Sumitomo Mitsui DS Asset Management Company Ltd Boosts Stake in Hologic, Inc. $HOLX

Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,257 shares of the medical equipment provider’s stock after buying an additional 763 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Hologic were worth $1,776,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Victory Capital Management Inc. increased its holdings in shares of Hologic by 34.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock worth $408,283,000 after buying an additional 1,692,177 shares during the last quarter. Nuance Investments LLC boosted its position in Hologic by 623.7% in the 1st quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider’s stock valued at $66,794,000 after buying an additional 931,920 shares during the period. Redwood Wealth Management Group LLC purchased a new position in Hologic in the 1st quarter valued at approximately $3,534,000. Invesco Ltd. boosted its position in Hologic by 18.8% in the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock valued at $298,655,000 after buying an additional 764,573 shares during the period. Finally, Nuveen LLC purchased a new position in Hologic in the 1st quarter valued at approximately $30,317,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HOLX. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research report on Tuesday, May 27th. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Stephens reissued an “overweight” rating and issued a $78.00 price target on shares of Hologic in a research report on Thursday. Finally, Morgan Stanley boosted their price target on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and an average target price of $79.38.

Hologic Price Performance

Hologic stock opened at $66.33 on Monday. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The firm has a fifty day moving average of $66.47 and a 200-day moving average of $62.75. The firm has a market capitalization of $14.75 billion, a P/E ratio of 27.52, a PEG ratio of 2.40 and a beta of 0.57. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business’s revenue was up 1.2% on a year-over-year basis. During the same period last year, the business earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.